Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||DLYE5953A||Case Reports/Case Series||Actionable||In a Phase I trial, a patient with triple-receptor negative breast cancer expressing Ly6e (IHC 3+), who progressed on prior treatments, achieved stable disease as best response with a 14% decrease of the primary tumor after 2 cycles of DLYE5953A treatment, but treatment was discontinued after cycle 5 due to disease progression (PMID: 32694157; NCT02092792).||32694157|